A beginners guide to CBD, Healthcare
NHS CBD Guidelines: What Doctors Can Actually Prescribe
Feb
Table of Contents
Medical cannabis became legal in the UK on 1st November 2018, yet accessing these treatments through the NHS remains extraordinarily difficult. Between March and June 2020, just 18 prescriptions for unlicensed cannabis-based products were dispensed across England.
This creates a striking contradiction. While millions of people use CBD oil products—with the market expected to exceed £1 billion by 2025—NHS prescriptions are exceptionally rare. Currently, only two cannabis-based medicines have received approval for NHS prescription. Doctors can prescribe these medications solely for severe conditions such as rare forms of epilepsy, chemotherapy-induced nausea, or muscle stiffness related to multiple sclerosis.
What can NHS doctors actually prescribe when it comes to medical cannabis, and why is access so restricted? We’ll examine the approved treatments, including Epidyolex—a CBD medicine endorsed by the National Institute for Health and Care Excellence (NICE) for specific epilepsy conditions. We’ll also explore the barriers preventing wider NHS access and the alternatives available for patients seeking CBD treatments.
For anyone considering CBD through the NHS, understanding these limitations and options is essential before speaking to your GP or consultant.
What is the legal status of CBD and medical cannabis in the UK?
The legal framework for cannabis and its derivatives changed significantly in 2018, though strict regulations remain in place. Understanding these laws is important for anyone considering CBD or cannabis-based treatments.
When did medical cannabis become legal?
Medical cannabis became legal in the UK on 1 November 2018, following amendments to the Misuse of Drugs Regulations 2001. The decision came after Home Secretary Sajid Javid responded to concerns from parents of children with severe epilepsy.
Two cases proved particularly influential in changing policy. Billy Caldwell (12) and Alfie Dingley (6), both children with epilepsy, showed remarkable improvements with cannabis-based treatments but faced legal barriers under previous UK law. Their families’ campaigns highlighted the gap between potential medical benefits and legal access.
The process began on 20 June 2018, when Health Secretary Jeremy Hunt announced support for medical cannabis use. Later, on 26 July 2018, Sajid Javid confirmed that cannabis products would become available for patients with “exceptional clinical need,” moving cannabis from Schedule I to Schedule II classification.
What’s the difference between CBD and THC?
Cannabis contains more than 100 chemical compounds called cannabinoids. Two compounds dominate: CBD (cannabidiol) and THC (tetrahydrocannabinol).
THC is the psychoactive component responsible for the “high” associated with cannabis. It remains a controlled substance in the UK and can only be prescribed by specialist doctors registered with the General Medical Council.
CBD has minimal psychoactive effects, and research suggests it may have anti-inflammatory properties. Pure CBD as an isolated substance is not controlled under the Misuse of Drugs Act 1971.
The distinction matters for consumers: medical cannabis can contain varying amounts of THC, while over-the-counter CBD products must contain no more than 0.2% THC, or 1mg per container. This threshold has been accepted for years, though discussions about reducing it to zero detectable THC have occurred.
Is CBD considered a controlled substance?
Pure CBD itself is not a controlled substance in the UK. However, the legal status becomes more complex with CBD-containing products.
For CBD products to be sold legally over-the-counter, they must:
- Be derived from EU-approved industrial hemp plants
- Contain no more than 0.2% THC in the final product
- Be listed on the Food Standards Agency’s Novel Food authorisation register
- Not make medical claims
CBD products containing controlled cannabinoids above the legal threshold are classified as Class B drugs under the Misuse of Drugs Act 1971, unless they meet the “exempt product” definition in regulations.
Additionally, CBD products for consumption must comply with Novel Food regulations, requiring companies to submit safety data and ingredient details.
The government has emphasised that legalising medical cannabis does not signal acceptance of recreational use. Unauthorised possession, supply, production, import or export of cannabis remains illegal, with penalties unchanged.
Can you get CBD on prescription through the NHS?
NHS CBD prescriptions remain extraordinarily rare despite widespread public interest in these treatments. Though technically possible, the reality stands far from common perceptions about availability.
Approved NHS CBD medications
The NHS has approved only three cannabis-based medicines for prescription:
Epidyolex – A highly purified liquid containing CBD without the psychoactive THC component. The National Institute for Health and Care Excellence (NICE) has approved its use alongside clobazam for treating specific forms of epilepsy.
Sativex (nabiximols) – A cannabis-based medicines mouth spray licensed specifically for adults with MS-related muscle spasticity that hasn’t responded to other treatments.
Nabilone – Prescribed by specialists to help relieve chemotherapy-induced nausea and vomiting, but only when other treatments have failed or aren’t suitable.
Conditions eligible for NHS prescribed CBD
NHS guidance restricts cannabis-based medicines to a very limited range of conditions:
- Rare, severe epilepsy – Children and adults with Lennox-Gastaut syndrome and Dravet syndrome specifically[112]
- Chemotherapy-related symptoms – Adults experiencing vomiting or nausea when other treatments haven’t worked
- Multiple sclerosis complications – People with muscle stiffness and spasms caused by MS
NHS prescribed CBD is typically only considered after patients have exhausted conventional treatment options. For instance, Epidyolex is recommended only after trying at least two other epilepsy medications without success.
Why NHS access is limited
Several significant barriers explain these remarkably low prescription rates:
Most clinicians cite insufficient evidence from randomised control trials demonstrating safety and clinical cost-effectiveness. Without robust research supporting wider applications, doctors remain hesitant to prescribe, particularly products containing THC.
Organisational bureaucracy creates substantial hurdles. Prescriptions require special pink pads that must be ordered specifically, and hospital consultants—not GPs—must initiate these prescriptions.
Funding presents a major obstacle. Even when clinicians agree a CBD prescription is appropriate, the cost of products and securing NHS funding approval often proves prohibitive. Many families report having to resort to private prescriptions, creating considerable financial burden.
There’s also a general lack of familiarity among UK doctors regarding medical cannabis. Many clinicians have received minimal training about these medications and express uncertainty about prescribing protocols.
Advocates argue that current resistance to prescribing fails to acknowledge patient experiences. Many doctors overlook evidence from “lived experience” whilst waiting for more clinical trials. This creates frustrating situations for patients who might benefit from these treatments but cannot access them through standard NHS channels.
How to get a CBD prescription privately in the UK
Private cannabis clinics have become the primary route for patients seeking medical cannabis treatments outside NHS restrictions. Since 2018, these clinics have expanded rapidly, offering access to cannabis-based medications for conditions that wouldn’t qualify for NHS prescriptions.
Eligibility criteria for private prescriptions
Private doctors can prescribe cannabis-based medicines for a much broader range of conditions than the NHS allows. You’ll need a diagnosed physical or mental health condition that hasn’t responded adequately to at least two conventional treatments.
Conditions commonly treated through private prescriptions include chronic pain, anxiety, depression, PTSD, sleep disorders, and neurological conditions. However, certain restrictions remain—private clinics won’t prescribe cannabis-based medicines during pregnancy or for patients with a history of psychosis or schizophrenia.
Most private clinics conduct preliminary assessments to evaluate whether patients might benefit from cannabis-based treatment, with the final consultation determining suitability.
Steps to get a private consultation
Obtaining a private CBD prescription follows a straightforward process:
- Research and select a suitable private cannabis clinic
- Complete an initial eligibility assessment (typically free of charge)
- Request your medical records from your GP surgery
- Book an initial consultation with a specialist doctor
- Receive your prescription if treatment is deemed appropriate
- Order medication through the clinic’s designated pharmacy
Many clinics now offer virtual consultations, making access more convenient. It’s worth noting that consultations don’t guarantee prescriptions—doctors must determine that cannabis-based treatment is appropriate for your specific circumstances.
Required documents and medical history
You’ll need to provide several documents for your private consultation:
Summary Care Records from your GP surgery are essential, along with evidence of previous treatments you’ve tried. You’ll also need proof of your diagnosis and valid identification matching your prescription details—this can be a passport, driving licence, or PASS card.
Some clinics may request additional documentation, such as evidence of physiotherapy or cognitive behavioural therapy, depending on your condition.
Costs involved in private treatment
Private CBD treatment involves several cost considerations:
| Service | Typical Cost Range |
|---|---|
| Initial consultations | £49-£200 |
| Follow-up appointments | £30-£70 |
| Monthly subscriptions | From £5/month |
| Annual plans | Around £50/year |
Several clinics offer access schemes to reduce costs. Some provide free follow-up consultations when patients contribute to medical cannabis research registries. Others offer discounted services for veterans or money-back guarantees if treatment proves unsuitable.
Medication costs are separate from consultation fees. Patients typically spend £1-£2.80 daily on medication, with monthly expenditure averaging £200-£300 for flower-based products. These costs can create a significant financial burden, particularly for patients requiring long-term treatment.
What types of CBD products can doctors prescribe?
Doctors have access to a limited range of cannabis-based medicines, each designed for specific medical conditions. Currently, only three products have received official licensing for medical use in the UK.
Licensed CBD medicines
1. Epidyolex
This highly purified liquid contains CBD without psychoactive THC components. Clinical trials have shown it can reduce seizures by up to 40% in some children. Epidyolex is specifically approved for treating Lennox-Gastaut syndrome and Dravet syndrome—both rare forms of epilepsy—usually prescribed alongside other anti-epileptic medications such as clobazam.
2. Sativex
Sativex (nabiximols) differs significantly from Epidyolex as it combines both CBD and THC in a mouth spray. This medication treats muscle stiffness and spasms in adults with multiple sclerosis when other treatments haven’t worked. Unlike pure CBD products, Sativex contains controlled amounts of the psychoactive THC component.
3. Nabilone
Prescribed by specialists to help relieve chemotherapy-induced nausea and vomiting, but only when other treatments have failed or aren’t suitable.
Other prescribed cannabis products
Beyond these licensed medicines, doctors may prescribe unlicensed cannabis-based medicinal products (CBMPs) in various forms:
- Oils and tinctures – Often prescribed with specific CBD:THC ratios
- Capsules – Providing controlled dosing with consistent content
- Oral sprays – Offering rapid absorption
- Flower products – Available through private prescription for certain conditions
How prescribed CBD differs from shop-bought products
Prescription CBD products undergo much stricter quality controls than commercial CBD supplements. They must meet pharmaceutical standards with extensive clinical testing and standardised dosing protocols.
Crucially, prescription products can contain precisely measured amounts of THC, whereas over-the-counter CBD must contain less than 0.2% THC. This allows doctors to prescribe products with specific ratios (such as 20:1 or 1:100) when appropriate.
Medical CBD also involves higher, carefully monitored doses under clinical supervision. This oversight enables personalised treatment plans rather than the general wellness approach of commercial CBD products.
If you’re considering CBD for a medical condition, it’s important to speak to your GP about whether prescription options might be more suitable than over-the-counter products.
Challenges and future of NHS medical cannabis access
Seven years after legalisation, NHS medical cannabis access remains extremely restricted. Understanding these barriers helps explain why most patients seeking CBD treatments must look beyond standard NHS channels.
Barriers to wider NHS adoption
The absence of large-scale randomised controlled trials represents the most significant obstacle. Most clinicians cite insufficient evidence of safety and cost-effectiveness. Fewer than five NHS prescriptions for unlicensed cannabis-based products are issued monthly.
However, the challenges extend beyond research gaps. Organisational barriers create substantial hurdles—prescriptions require special pink pads and must be initiated by hospital consultants rather than GPs. Many clinicians also express concerns about long-term THC exposure, particularly potential mental health impacts.
Cost presents another major barrier. Even when clinicians believe CBD treatments may be appropriate, securing NHS funding approval often proves difficult. This forces many families towards expensive private alternatives.
Ongoing research and clinical trials
Despite the urgent need for evidence, progress remains slow. No publicly-funded medical cannabis trials have produced results in the five years since legalisation. The National Institute for Health and Care Research (NIHR) confirmed that two epilepsy-related trials remain “under operational consideration” but haven’t commenced.
A planned study investigating cannabidiol for psychosis (CANTOP-RCT) has been abandoned, primarily “due to difficulties in securing a supply of cannabidiol”. Cannabis presents unique research challenges—as a botanical medicine containing hundreds of components, it doesn’t fit traditional pharmaceutical assessment approaches.
Will NHS CBD guidelines change soon?
Several organisations are advocating for guideline reforms. Experts call for improved doctor education, expanded NICE guidelines, and NHS funding for approved prescriptions. There are growing calls for real-world evidence to inform prescription decisions alongside traditional clinical trials.
Some developments appear promising. Clinical trials evaluating cannabis medicines for epilepsy are expected to begin in 2025. Research suggests that improved NHS access could potentially add £13 billion to the economy through productivity gains.
However, significant reform would require coordinated leadership from the Department of Health, Home Office, and NICE. Until this occurs, most patients will likely continue relying on private clinics or over-the-counter CBD products with their inherent limitations.
If you’re considering medical cannabis for a specific condition, it’s worth discussing all available options with your GP or specialist, even if NHS prescribing remains limited.
Conclusion
Medical cannabis became legal in the UK in 2018, yet NHS prescriptions remain remarkably scarce. Patients who might benefit from CBD treatments continue to face substantial obstacles accessing them through standard healthcare channels.
The gap between legal availability and practical access is significant. NHS doctors can prescribe only three approved cannabis medicines—Epidyolex, Sativex, and Nabilone—for very specific conditions. These treatments are reserved for rare forms of epilepsy, multiple sclerosis-related muscle spasticity, and chemotherapy-induced nausea when other options have failed.
For most patients, this creates two main pathways: meet the stringent NHS criteria or pursue private treatment. Private prescriptions offer access to CBD for conditions like chronic pain and anxiety, but costs typically range from £80-£300+ monthly. This financial barrier means many people turn to over-the-counter CBD products, which lack the clinical oversight and quality controls of prescribed medicines.
If you’re considering CBD for any health condition, you should speak to your GP or other healthcare professional to discuss whether it’s appropriate for your situation.
Research planned for 2025 might eventually expand NHS access, particularly for epilepsy treatments. However, significant barriers persist, including limited clinical trial evidence, bureaucratic hurdles, and funding constraints. Until these systemic issues are addressed, most patients seeking CBD treatments will likely continue relying on private clinics or commercial products.
The current situation highlights a complex healthcare challenge—treatments that are legally available yet practically inaccessible through the NHS for the majority who might benefit from them. Understanding these limitations helps patients make informed decisions about their treatment options.
This article is provided for general information only and should not be treated as a substitute for medical advice from your GP or other healthcare professional. Always consult with a qualified medical practitioner before starting any new treatment.
Key Takeaways
Despite medical cannabis being legal since 2018, NHS CBD access remains extremely limited with practical alternatives available through private clinics.
• Only three CBD medications are NHS-approved: Epidyolex for rare epilepsy, Sativex for MS spasticity, and Nabilone for chemotherapy nausea • NHS prescribed just 18 unlicensed cannabis products between March-June 2020, highlighting exceptionally restrictive access criteria • Private CBD prescriptions cost £80-£300+ monthly but offer treatment for broader conditions like chronic pain and anxiety • Prescribed CBD differs significantly from over-the-counter products through stricter quality controls and higher, clinically-supervised dosages • Lack of randomised trials and bureaucratic barriers prevent wider NHS adoption, forcing most patients toward private treatment options
The current system creates a healthcare paradox where legal treatments remain practically inaccessible through standard NHS channels, leaving patients to navigate expensive private alternatives or unregulated commercial CBD products.
FAQs
Q1. Can NHS doctors prescribe CBD in the UK? Yes, NHS doctors can prescribe CBD, but it’s extremely limited. Only three cannabis-based medicines are currently approved: Epidyolex for rare forms of epilepsy, Sativex for multiple sclerosis-related muscle spasticity, and Nabilone for chemotherapy-induced nausea. These are prescribed only when other treatments have failed.
Q2. What conditions are eligible for NHS-prescribed CBD? NHS-prescribed CBD is primarily considered for rare, severe forms of epilepsy (like Lennox-Gastaut syndrome and Dravet syndrome), chemotherapy-induced nausea and vomiting, and muscle stiffness caused by multiple sclerosis. These prescriptions are typically only considered after conventional treatments have been exhausted.
Q3. How can I get a CBD prescription privately in the UK? To obtain a private CBD prescription, you need to have a diagnosed condition that hasn’t responded to at least two conventional treatments. The process involves selecting a private cannabis clinic, completing an eligibility assessment, obtaining medical records, booking a consultation with a specialist, and if approved, receiving a prescription. Costs can range from £80 to £300+ monthly.
Q4. What’s the difference between prescribed CBD and over-the-counter products? Prescribed CBD products adhere to stricter regulations and quality controls than commercial CBD. They undergo extensive clinical testing with standardised dosing protocols. Prescribed products can contain precisely calibrated amounts of THC, whereas commercial CBD must contain less than 0.2% THC. Medical CBD also typically involves higher, carefully monitored doses under clinical supervision.
Q5. Why is NHS access to CBD so limited? NHS access to CBD remains limited due to several factors. These include a lack of large-scale randomised controlled trials, organisational bureaucracy, funding constraints, and concerns about long-term THC exposure. Many clinicians also cite insufficient evidence of safety and cost-effectiveness as reasons for hesitancy in prescribing CBD-based treatments.